The Efficacy and Safety of Lebrikizumab Monotherapy for the Management of Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Feb 2

PMID 36726353

Authors

Bader Bashrahil

Ziyad Alzahrani

Sahal Samarkandy

Abdullah Aman

Abdulhadi Jfri

Affiliations

Soon will be listed here.

Abstract

Background: Atopic dermatitis (AD) is a chronically relapsing disease. Few biologics are approved for moderate-to-severe AD, and novel interventions are emerging. We aimed to evaluate the safety and efficacy of lebrikizumab, an IL-13 immunomodulator, as monotherapy vs. placebo in treating moderate-to-severe AD.

Methods: Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, and ClinicalTrials.gov registry (CT.gov) databases were systematically searched. We evaluated lebrikizumab vs. placebo and measured efficacy using Eczema Area and Severity Index (EASI), Body Surface Area (BSA), and Investigator's Global Assessment (IGA) change from baseline to week 16. Safety was evaluated by the incidence of serious adverse events (SAEs), non-serious adverse events (NSAEs), and mortality. The risk of bias was investigated using the Revised Cochrane risk of bias tool.

Results: Three RCTs ( = 1,149) included 543 (47.25%) men vs. 606 (52.75%) women. Meta-analysis showed statistically significant improvement in EASI, IGA, and BSA. EASI75 at week 16 for all regimens was (RR = 2.62, 95% CI [2.06, 3.34], < 0.00001) with the first regimen (500 mg loading dose then 200 mg every 2 weeks) showing the most significant improvement (RR = 3.02, 95% CI [2.39, 3.82], < 0.00001). The pooled analysis of safety outcomes concluded that lebrikizumab did not correlate significantly with the incidence of SAEs, NSAEs, and mortality.

Conclusion: Overall, lebrikizumab showed a significant improvement in all efficacy outcomes. Additionally, it did not contribute to any significant incidence of SAEs, NSAEs, or mortality. The risk of bias in included RCTs was minor except in the randomization domain. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessment of the outcomes ranged from low to high, but predominantly high certainty of evidence.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022362438.

Citing Articles

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.

Lin J, Luo M, Zhuo Q, Chen N, Zhang H, Han Y Front Pharmacol. 2024; 15:1429709.

PMID: 39629076 PMC: 11611541. DOI: 10.3389/fphar.2024.1429709.

References

Spergel J, Boguniewicz M, Paller A, Hebert A, Gallagher P, McCormick C . Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol. 2007; 157(2):378-81. DOI: 10.1111/j.1365-2133.2007.08001.x. View

Lassus A . Clinical comparison of alclometasone dipropionate cream 0.05% with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in children. J Int Med Res. 1983; 11(5):315-9. DOI: 10.1177/030006058301100512. View

Perche P, Cook M, Feldman S . Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. Ann Pharmacother. 2022; 57(1):86-98. DOI: 10.1177/10600280221096713. View

Breuer K, Werfel T, Kapp A . Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005; 6(2):65-77. DOI: 10.2165/00128071-200506020-00001. View

Carlsten C, Dimich-Ward H, Ferguson A, Watson W, Rousseau R, Dybuncio A . Atopic dermatitis in a high-risk cohort: natural history, associated allergic outcomes, and risk factors. Ann Allergy Asthma Immunol. 2012; 110(1):24-8. DOI: 10.1016/j.anai.2012.10.005. View

Leung D . Role of IgE in atopic dermatitis. Curr Opin Immunol. 1993; 5(6):956-62. DOI: 10.1016/0952-7915(93)90112-6. View

Sedeh F, Henning M, Jemec G, Ibler K . Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2022; 102:adv00764. PMC: 9574696. DOI: 10.2340/actadv.v102.2075. View

Williams H, Stewart A, von Mutius E, Cookson W, Anderson H . Is eczema really on the increase worldwide?. J Allergy Clin Immunol. 2007; 121(4):947-54.e15. DOI: 10.1016/j.jaci.2007.11.004. View

Eichenfield L, Tom W, Berger T, Krol A, Paller A, Schwarzenberger K . Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014; 71(1):116-32. PMC: 4326095. DOI: 10.1016/j.jaad.2014.03.023. View

10.

Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T . Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013; 68(4):498-506. PMC: 7159470. DOI: 10.1111/all.12112. View

11.

Yawalkar S, Schwerzmann L . Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol. 1991; 25(6 Pt 2):1163-6. DOI: 10.1016/0190-9622(91)70318-v. View

12.

El-Batawy M, Bosseila M, Mashaly H, Hafez V . Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009; 54(2):76-87. DOI: 10.1016/j.jdermsci.2009.02.002. View

13.

Korting H, Schollmann C, Cholcha W, Wolff L . Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. J Eur Acad Dermatol Venereol. 2010; 24(10):1176-82. DOI: 10.1111/j.1468-3083.2010.03616.x. View

14.

Spergel J . From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010; 105(2):99-106. DOI: 10.1016/j.anai.2009.10.002. View

15.

Sidbury R, Davis D, Cohen D, Cordoro K, Berger T, Bergman J . Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014; 71(2):327-49. PMC: 4410179. DOI: 10.1016/j.jaad.2014.03.030. View

16.

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

17.

Simpson E, Flohr C, Eichenfield L, Bieber T, Sofen H, Taieb A . Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018; 78(5):863-871.e11. DOI: 10.1016/j.jaad.2018.01.017. View

18.

Chiang C, Eichenfield L . Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009; 26(3):273-8. PMC: 2762386. DOI: 10.1111/j.1525-1470.2009.00911.x. View

19.

Johnson B, Franco A, Beck L, Prezzano J . Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019; 12:181-192. PMC: 6432884. DOI: 10.2147/CCID.S163814. View

20.

Boguniewicz M, Fiedler V, Raimer S, Lawrence I, Leung D, Hanifin J . A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998; 102(4 Pt 1):637-44. DOI: 10.1016/s0091-6749(98)70281-7. View